Nasdaq

Lexaria Bioscience Enters GLP-1 Market Race

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience is advancing its DehydraTECH drug delivery platform to compete in the booming GLP-1 market, which is dominated by Novo Nordisk’s ...
Nasdaq

Lexaria Bioscience Advances GLP-1 Study

Lexaria Bioscience (LEXX) has released an update. Lexaria Bioscience has received ethics board approval for its 12-week Phase 1b GLP-1 study, which focuses on diabetes and weight loss, marking a ...
Business Wire

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

- Proof-of-activity now established for PBGENE-HBV, the first and only clinical modality designed to eliminate covalently closed circular DNA (cccDNA) and inactivate integrated DNA, with the goal of ...
Morningstar

Alligator Bioscience Presents OPTIMIZE-1 Biomarker Data at ASCO 2025 Annual Meeting

LUND, SE / ACCESS Newswire / May 23, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX) today announced the presentation of biomarker data from its OPTIMIZE-1 clinical trial at the 2025 American ...
Morningstar

Replicate Bioscience Announces Publication of Promising New Phase 1 Durability Data for Its srRNA Vaccine Candidate RBI-4000

Eight month follow-up data published in Communications Medicine, a Nature portfolio journal Full clinical dataset supports further development of RBI-4000 as a next generation vaccine approach for ...